(KURA) Kura Oncology, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KURA) Kura Oncology, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Kura Oncology, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Ziftomenib in NPM1-mutated AML
Ziftomenib is Kura Oncology, Inc.'s lead menin inhibitor and the clearest late-stage growth driver as of end-2025. NPM1-mutated AML affects about 30% of adult AML cases, making it a genetically defined, high-need niche with strong drug demand. The program sits in Kura Oncology, Inc.'s Stars bucket because it targets a large unmet need with active late-stage development interest.
Ziftomenib in KMT2A-rearranged AML
Ziftomenib is Kura Oncology’s second core leukemia shot, aimed at KMT2A-rearranged AML, a rare subtype that makes up about 5% to 10% of AML and still lacks durable standard options. The menin-inhibitor class is expanding fast, and early clinical data have shown meaningful activity in this high-risk setting, supporting its Stars status in the BCG matrix.
Ziftomenib in acute leukemia combinations
Kura Oncology, Inc. is pushing ziftomenib into AML combinations, including venetoclax and azacitidine, not just monotherapy. In KOMET-007, this broader path targets both newly diagnosed and relapsed NPM1-mutant AML, which can lift addressable patients beyond a narrow single-agent niche. That keeps the asset in a high-investment, high-upside slot.
Oral menin inhibitor platform
Kura Oncology, Inc.’s oral menin inhibitor platform is a clear Star: ziftomenib is the lead asset, and menin inhibition is one of the hottest areas in acute leukemia, especially NPM1-mut AML and KMT2A-rearranged disease. With AML a high-unmet-need market and Kura focused almost entirely on this franchise, the platform is its main growth engine.
- Lead asset: ziftomenib
- Focus: acute leukemia
- Best fit: high-growth Star
Most advanced company asset
Ziftomenib is Kura Oncology, Inc.'s most advanced asset and the clear Star in its BCG view as of end-2025. It is the lead menin inhibitor in the pipeline, with the strongest clinical and near-term commercial path; by 2025, Kura had pushed it into late-stage development for NPM1-mutated AML, the biggest value driver in the Company.
- Lead program; late-stage asset
- Best clinical and commercial fit
- Closest to Star status at end-2025
Ziftomenib: Kura’s Lead Growth Engine in AML
Ziftomenib is Kura Oncology, Inc.'s Star asset: the lead menin inhibitor and the main growth driver in 2025/2026. NPM1-mutated AML is about 30% of adult AML, and KMT2A-rearranged AML is 5% to 10%, giving the franchise a large, high-need target base.
| Star asset | 2025/2026 signal |
|---|---|
| Ziftomenib | Late-stage AML; broad combo push |
| NPM1-mut AML | ~30% of adult AML |
| KMT2A-r AML | ~5% to 10% of AML |
What is included in the product
Detailed Word Document
Kura Oncology BCG Matrix: pipeline assets mapped into Stars, Question Marks, Cash Cows, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Kura Oncology BCG Matrix for quick portfolio prioritization and clearer strategic decisions
Reference Sources
Provides a clear source trail for Kura Oncology, Inc., boosting credibility and helping investors verify key claims fast.
Cash Cows
0 approved products
0 approved products means Kura Oncology had no marketed therapy as of end-2025, so there was no mature cash cow to fund the business. With no product revenue, the company remained clinical-stage and still depended on outside capital and partnerships to finance R&D. In BCG terms, this is a zero-cash-franchise profile, not a steady cash generator.
0 recurring product sales
Kura Oncology reported 0 commercial product sales in 2025, so it has no approved drug to generate a steady cash cow stream. With no low-growth revenue base to milk, cash generation still depends on financing and partnership income. That makes the business more like a development-stage biotech than a mature BCG cash cow.
0 royalty stream
Kura Oncology, Inc. is not a royalty-heavy commercial biotech: its latest filing shows 0 royalty revenue, and no durable royalty asset stands out in the pipeline mix. That leaves this BCG cell with no real cash-cow engine. The model is still built on clinical assets and future launches, not steady royalty cash.
0 mature low-growth brands
Kura Oncology, Inc. has 0 cash-cow brands because it still lacks a mature, revenue-generating drug franchise. Its portfolio at end-2025 remained centered on investigational oncology assets, so there is no established product in a low-growth market. With no approved drug sales to support stable cash flow, this BCG segment stays empty.
- No mature brand at end-2025
- Portfolio remains investigational
- No stable product cash flow
- Zero cash cows in BCG terms
No cash cow identified
Kura Oncology, Inc. has no true cash cow because it still has no approved oncology product to harvest. In FY2025, the business remained pipeline-led, so value depends on clinical and regulatory conversion, not on steady product cash flow.
That means any future cash cow would have to come from a successful approval and launch, not from an existing mature franchise. Until then, the portfolio sits in a development stage, with cash use tied to R&D and trials rather than operating surplus.
- No approved product to monetize.
- FY2025 value stayed pipeline-driven.
- Cash cow needs FDA approval first.
Kura Oncology Lacks Cash Cows in FY2025
Cash Cows are effectively absent for Kura Oncology, Inc. in FY2025. The company reported 0 approved products, 0 commercial product sales, and 0 royalty revenue, so there was no mature franchise generating steady cash. Its profile stayed pipeline-led, not harvest-led.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Commercial product sales | 0 |
| Royalty revenue | 0 |
Get Your Copy
Kura Oncology, Inc. Reference Sources
You're previewing the exact Kura Oncology, Inc. BCG Matrix report you'll receive after purchase. The file is the same fully formatted document—no samples, no watermarks, and no hidden pages. Once purchased, it’s ready for immediate download, editing, or presentation.
Dogs
Tipifarnib broad monotherapy
Tipifarnib broad monotherapy is a Dog in Kura Oncology, Inc.'s BCG view: it is an older farnesyltransferase inhibitor with little traction outside biomarker-selected uses. As of end-2025, it still had no FDA approval and no large installed base, so broad sales upside stayed weak. The oncology field is crowded, and 2025 filings showed Kura still depended on a narrow clinical path rather than commercial scale.
Tipifarnib unselected solid tumors
Tipifarnib in unselected solid tumors is a weak BCG fit because the addressable share stays tiny without biomarker screening. HRAS alterations, the clearest response driver, are usually under 1% to 4% in many solid tumors, so broad use dilutes the drug’s case. Kura Oncology, Inc. has stronger economics in selected subsets, not non-selected expansion.
Tipifarnib non-biomarker blood cancers
Tipifarnib has been tested in hematologic cancers beyond its biomarker-led niches, but the lack of a precise biomarker makes broad share gain unlikely. That keeps these programs outside Kura Oncology, Inc.’s main value driver, where the better shot is in cleaner, high-response segments. In a BCG view, these are Dogs: low strategic fit, weak differentiation, and hard-to-scale demand.
Legacy farnesyl transferase inhibitor work
Tipifarnib is Kura Oncology, Inc.’s legacy farnesyl transferase inhibitor, and that older mechanism sits in the Dogs bucket. In oncology, older classes often lose share to newer targeted drugs, so growth visibility is weaker than for Kura Oncology, Inc.’s menin program. Tipifarnib still has clinical value, but it is not the main value driver.
- Older class, weaker growth
- Farnesyl transferase inhibitor
- Menin program has better upside
- Dog in BCG terms
No approved legacy franchise
As of year-end 2025, Kura Oncology, Inc.’s legacy portfolio still had no approved product, so it had not built a durable revenue base. Assets without approval and without clear differentiation usually act like Dogs: they keep drawing development spend while giving little cash back. That makes the franchise a capital drag, not a cash engine.
- No approved legacy product in 2025
- Low cash return, high R&D burn
- Weak fit for Dogs in BCG terms
Tipifarnib Remains a Weak-Return Dog for Kura Oncology
Dogs in Kura Oncology, Inc.’s BCG view are still the legacy tipifarnib programs: older mechanism, no FDA approval at year-end 2025, and limited scale beyond small biomarker-led niches. HRAS alterations stay rare, often under 1% to 4% in many solid tumors, so broad demand is weak and R&D spend is more likely to drain cash than build it.
| Dog asset | Key 2025 data | BCG read |
|---|---|---|
| Tipifarnib | No approval; niche use only | Weak share, low cash return |
| Unselected solid tumors | HRAS often 1% to 4% | Small addressable market |
Question Marks
KO-2806 solid-tumor program
KO-2806 is Kura Oncology, Inc.'s newer solid-tumor asset and still sits in Phase 1/2 development, so it has no commercial share or product sales yet. That makes it a classic Question Mark: high upside if clinical data and later-stage trials work, but still early and capital-heavy. In 2025, Kura Oncology, Inc. remained pre-commercial, so KO-2806’s value is driven by pipeline readouts, not revenue.
Tipifarnib plus alpelisib
Tipifarnib plus alpelisib is Kura Oncology’s Novartis-backed bet in biomarker-selected head and neck squamous cell carcinoma, aimed at HRAS-overexpressing or PIK3CA-altered tumors. The niche looks attractive because it targets clear molecular subgroups, but it still has zero commercial share since it remains in clinical development.
Kura reported cash and cash equivalents of $389.5 million at 2025 year-end, so this program still depends on outside capital to move from Question Mark to Star. If later data show durable responses in a defined patient slice, the asset could gain value fast; if not, it stays a cash drain.
Ziftomenib in ALL
Ziftomenib in acute lymphoblastic leukemia is a Question Mark for Kura Oncology, Inc.: the market is high-need, with ALL making up about 1% of U.S. cancer cases, but Kura has no approved ALL asset yet. The drug is only being explored beyond AML, so the upside is real but still unproven. Until clinical data and regulatory traction arrive, this stays a high-risk, high-potential bet.
Ziftomenib expansion beyond core AML
Ziftomenib’s expansion beyond core AML could lift Kura Oncology, Inc.’s addressable market if combo and new-indication data hold up. This is still a Question Mark: growth is real, but it is not de-risked until larger, cleaner datasets show efficacy and safety beyond the initial AML setting.
- Broadening use can raise TAM.
- Success still depends on trial proof.
- Positive data could shift it to Star.
Biomarker expansion studies
Kura Oncology, Inc.'s biomarker expansion studies fit the Question Marks box: they target genetically defined subsets, but none has built clear market share yet. These programs can become future winners if response rates hold up in later trials, but they also demand heavy R&D spend and carry high failure risk.
- High upside, no share today
- Driven by biomarker fit
- Cash burn stays elevated
Kura’s early-stage bets: funded, but still far from de-risked
Kura Oncology, Inc.'s Question Marks are still early, data-driven bets: KO-2806, tipifarnib plus alpelisib, and ziftomenib beyond AML all have no commercial share yet. The upside is tied to trial wins in small, biomarker-defined groups, but each program still burns cash and needs more proof. Kura Oncology, Inc. ended 2025 with $389.5 million in cash and cash equivalents, so these assets remain funded but not de-risked.
| Program | Status | 2025 signal |
|---|---|---|
| KO-2806 | Phase 1/2 | No sales |
| Tipifarnib + alpelisib | Clinical | Biomarker niche |
| Ziftomenib | Expansion | Pre-commercial |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.